Disease Trajectories and Anti-cytokine Response Signatures in Atopic Dermatitis and Psoriasis

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age0-100
SponsorUniversity Hospital Schleswig-Holstein

About this trial

The clinical study investigates the long-term course of disease in patients with chronic inflammatory skin diseases (atopic eczema and psoriasis) and the impact of tarheted therapies on the clinical and molecular level. For this purpose, patients are asked to take part in regular examinations and data collections, and to donate biomaterials (blood, skin biopsies, skin swabs, tape strips, stool samples). Blood samples are used to analyze inflammation messengers. Punch biopsies from lesional and non-lesional skin areas are used to analyze gene expression. Tape strips are pieces of transparent adhesive tapes to strip off most of the horny layer that will be used to examine mRNA and protein expression. The skin smears are superficial smears of three areas of skin with cotton swabs, which are used to examine bacteria on the skin. Overall, the study will help to monitor the disease course clinically and on the molecular level in participating patients for at least ten years and to collect information about the impact of various external factors including treatments. The study has no effect on the therapies of the disease, it serves only the accompanying data collection

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Patients with a clinical diagnosis of atopic dermatitis, psoriasis or autoimmune skin disease

Written informed consent obtained from the subject

Disqualifiers

Patients who decline participation

Trial population

Patient who are beeing treated in the routine care with chronic inflammatory skin diseases will be asked to participate in this project.

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

  • Biosampling for molecular analysis

    Other intervention

    Observational study with no therapeutic intervention. Biosampling for molecular analysis

Treatment groups

1,000 Participants
are divided into 2 treatment groups
Group A: Atopic dermatitis1 intervention
Group B: Controls1 intervention

Trial outcomes

Primary outcomes

1

Disease progression

Epidemiological and phenotypical data of patients

Time frame
10 years
2

Molecular signature changes

Molecular signatures will be measured using OMICS and sequencing technologies

Time frame
10 years

Secondary outcomes

1

Development of comorbidities

Assessment of newly developed comorbid diseases over time

Time frame
10 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.